Evidence Trace, complete trial record

In plain terms

In plain terms: Mesenchymal stem cell therapy (intravenous, allogeneic laromestrocel) shows early signals in human research but the evidence is limited -- small trials, surrogate endpoints, or not yet independently replicated. It is an emerging area, not yet a proven one.

Mesenchymal stem cell therapy (intravenous, allogeneic laromestrocel)

C Limited: small, mixed or unreplicated trials

Category Devices

Evidence Randomized human trials, one at moderate scale, unreplicated

Reviewed August 2026

PMIDs 41747733 · 28977399 · 38679727 · 42019090 · 42737497

The endpoint this grade is based on: Objectively measured functional outcome

The evidence as the record states it

Evidence record

PMID 41747733 PMID 28977399 PMID 38679727 PMID 42019090 PMID 42737497

Ruiz et al. (Cell Stem Cell, 2026; PMID 41747733) - randomized dose-finding trial, N=148 ambulatory adults with frailty, allogeneic bone-marrow MSCs (laromestrocel). Primary endpoint was the 6-minute walk test: +63.4 m versus placebo at month 9 (95% CI 17.1 to 109.6, p=0.0077), but +41.3 m at month 6 did not reach significance (95% CI -2.4 to 84.9, p=0.0635). Tompkins et al. (J Gerontol A Biol Sci Med Sci, 2017; PMID 28977399) - phase II randomized double-blind placebo-controlled dose-finding study in 30 patients with aging frailty whose primary endpoint was safety; the 6-minute walk improvement was a secondary finding in the 100 million cell group only, with no gain at 200 million cells. Zhu et al. (Stem Cell Res Ther, 2024; PMID 38679727) - randomized double-blind placebo-controlled trial of umbilical cord-derived MSCs in aging frailty; the primary endpoint was the SF-36 physical component score, which is self-reported; among objective secondary outcomes, timed up and go and grip strength improved while the 4-meter walk did not (p=0.21). Nguyen et al. (EBioMedicine, 2026; PMID 42019090) - open-label randomized phase 2 trial of umbilical cord-derived MSCs in 147 frail adults aged 60 to 85, funded by the hospital's parent company; Short Physical Performance Battery 1.1 points higher at nine months. Poutouri et al. (Int J Mol Sci, 2026; PMID 42737497) - systematic review of the three randomized frailty trials: signals of benefit on mobility, heterogeneity too great to pool. Grade C. Funding: Ruiz 2026 (PMID 41747733) was supported by NIH grants and its senior author is chief scientific officer, a paid consultant, a board member and an equity holder of Longeveron Inc., which makes the cells tested; Tompkins 2017 (PMID 28977399) was funded by the Soffer Family Foundation and the Starr Foundation, with Longeveron employees and consultants among the authors and the same senior author a Longeveron shareholder; Zhu 2024 (PMID 38679727) was funded by Chinese government programs with no company involvement declared.

PMID 41747733 PMID 28977399 PMID 38679727 PMID 42019090 PMID 42737497

Why Grade C and not Grade B

Grade C reflects early or limited human evidence -- small trials, surrogate endpoints, or preliminary findings not yet independently replicated. The evidence points in a promising direction but does not yet meet the standard for Grade B. A single well-powered, independently replicated trial with a meaningful endpoint would move this to Grade B or higher.

What this grade covers and what it does not

Grade C. The evidence is better than the category's reputation and weaker than its marketing. WHAT SUPPORTS IT: Ruiz 2026 (PMID 41747733) is a genuine randomized trial at moderate scale whose primary endpoint was objectively measured function, not a biomarker. The 63.4 m point estimate clears every published threshold for a meaningful change in 6-minute walk distance in older adults, including the large-change mark near 50 m. The 95% confidence interval runs from 17.1 to 109.6 m, and its lower bound sits below the minimal important difference reported for frail older adults, so the trial is consistent with an effect that matters and equally consistent with one that does not. An objectively measured functional outcome does not cap the grade under the EBL rubric, so B was arguable. WHY IT IS HELD AT C: nothing has replicated it with the same product, and the rubric puts a single positive trial no one has independently repeated at C however well run it is. Two randomized trials of a different product, umbilical cord-derived cells, reported better grip strength and timed up and go as secondary endpoints (Zhu 2024, PMID 38679727) and a higher Short Physical Performance Battery score in an open-label design (Nguyen 2026, PMID 42019090); a different cell source in an unblinded trial does not replicate laromestrocel, and a 2026 systematic review found the three trials too heterogeneous to pool (Poutouri 2026, PMID 42737497). The same trial's month 6 result also did not reach significance (p=0.0635), so the primary endpoint was met at one timepoint and missed at another inside one dose-finding study. Tompkins 2017 (PMID 28977399) enrolled 30 people with safety as its primary endpoint, and its walk gain appeared in one dose group only; Zhu 2024 (PMID 38679727)'s primary endpoint was self-report. B would assert the effect is established, and it is not. WHAT THIS DOES NOT COVER: every trial cited here enrolled people with diagnosed aging frailty and measured physical function. None studied healthy adults, none measured lifespan, and none supports the general rejuvenation claim under which this is usually sold. WHAT THIS RECORD GRADES: intravenous allogeneic bone marrow-derived cells of one developer, laromestrocel, in diagnosed aging frailty. Umbilical cord, adipose and other MSC products sold in clinics are different products and are not graded by these trials. Every laromestrocel trial is maker-linked, as the funding line states.

What would move this grade

A well-powered randomized trial with an objective, clinically meaningful primary endpoint and at least one independent replication would support Grade B or higher.

How to track whether this is working 6-minute walk distance, gait speed, grip strength. Not a biomarker panel.